Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corporation

Bausch + Lomb Corporation ( ($BLCO) ) just unveiled an announcement. Bausch + Lomb has launched its preloaded enVista Envy full range of vision int...

Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH)

Bausch + Lomb Corporation ( ($BLCO) ) has issued an update. Bausch + Lomb will showcase extensive new scientific data and host multiple educational...

Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting

Bausch + Lomb Corporation ( ($BLCO) ) has shared an announcement. Bausch + Lomb Corporation will report its first-quarter 2026 financial results on...

Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lifecore Biomedical (LFCR), Pyxis Oncology (PYXS) and Bausch + Lo...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lifecore Biomedical (LFCR), Pyxis Oncology (PYXS) and Bausch + Lomb Corporation (BLCO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evotec AG (EVO – Research Report), Shoulder Innova...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BLCO	$16.43	+3.20%	181.83K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BLCO	$16.43	+3.2%	181.83K
3
4
5
6

BLCO

BLCO

Dividend Overview

Get Bausch + Lomb Corporation Data in Excel

Get Bausch + Lomb Corporation Data in Excel